Payment overview · 2025
General Payments
$954.72
52 reported records · 17 companies
Healthcare provider profile · identity verified
John Walter Bulger, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MISHAWAKA, IN · NPI 1821123035
Verified facts
What the public records show
CMS Open Payments records show John Walter Bulger, M.D. received $954.72 in general payments during 2025 across 52 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $205.08 | 21.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.46 | 17.3% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $84.09 | 8.8% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.89 | 7.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.59 | 6.9% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $61.21 | 6.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.16 | 4.5% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $42.36 | 4.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.70 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.09 | 3.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.30 | 3.4% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $28.69 | 3.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.08 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.44 | 1.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.67 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.99 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.92 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $954.72 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $205.08 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.75 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $84.09 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $71.89 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $65.59 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $61.21 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $28.69 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 491 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 411 | 54 |
| Gabapentin | Gabapentin | 343 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 75 |
| Alprazolam | Alprazolam | 183 | 24 |
| Pregabalin | Pregabalin | 161 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 48 |
| Omeprazole | Omeprazole | 147 | 47 |
| Lisinopril | Lisinopril | 145 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 51 |
| Trazodone Hcl | Trazodone Hcl | 137 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 41 |
| Clonazepam | Clonazepam | 114 | 15 |
| Losartan Potassium | Losartan Potassium | 96 | 27 |
| Tramadol Hcl | Tramadol Hcl | 95 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 34 |
| Morphine Sulfate Er | Morphine Sulfate | 86 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 29 |
| Simvastatin | Simvastatin | 81 | 24 |
| Furosemide | Furosemide | 80 | 31 |
| Ezetimibe | Ezetimibe | 78 | 29 |
| Meloxicam | Meloxicam | 76 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 28 |
| Cephalexin | Cephalexin | 65 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 26 |
| Prednisone | Prednisone | 62 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 26 |
| Glipizide Er | Glipizide | 61 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 19 |
| Lorazepam | Lorazepam | 60 | 14 |
| Metformin Hcl | Metformin Hcl | 57 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Oxycontin | Oxycodone Hcl | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 14 |
| Ozempic | Semaglutide | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 20 |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Montelukast Sodium | Montelukast Sodium | 41 | 19 |
| Naproxen | Naproxen | 41 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 31 |
| Baclofen | Baclofen | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 13 |
| Temazepam | Temazepam | 36 | suppressed |
| Eliquis | Apixaban | 35 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Diazepam | Diazepam | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Xtampza Er | Oxycodone Myristate | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 18 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | 11 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | 11 |
| Famotidine | Famotidine | 24 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Lidocaine | Lidocaine | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $954.72 · 52 records | Otsuka America Pharmaceutical, Inc. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, INGREZZA, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, SMARTVEST, UBRELVY, VRAYLAR, Veozah, XTAMPZA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error